BioMarin Pharmaceutical (BMRN) : The value of composite uptick trades was $24.84 million, whereas, the value of composite downtick trades was $33.63 million. The uptick to downtick ratio stood at 0.74 with a negative money flow of ($8.79) Million during Mondays trading session. The block trades money flow was negative ($6.88 million).The uptick to the downtick ratio of 0.12 in block trades signals that the large investors have utilized the rise in the stock to sell.The uptick transaction value stood at $0.96 million. The transaction of the trades on downticks amounted to $7.84 million, which confirms investors selling on the strength of price. BioMarin Pharmaceutical (BMRN) gained 43 cents at $92.44, an increase of 0.47% over the previous days close.
BioMarin Pharmaceutical Inc. has dropped 5.97% in the last five trading days, however, the shares have posted positive gains of 1.12% in the last 4 weeks. BioMarin Pharmaceutical Inc. is up 7.68% in the last 3-month period. Year-to-Date the stock performance stands at -11.12%.
BioMarin Pharmaceutical (NASDAQ:BMRN): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $92.90 and $92.30 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $94.22. The buying momentum continued till the end and the stock did not give up its gains. It closed at $93.11, notching a gain of 0.72% for the day. The total traded volume was 1,835,337 . The stock had closed at $92.44 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Spiegelman Daniel K, officer (EVP, Chief Financial Officer) of Biomarin Pharmaceutical Inc, had unloaded 4,000 shares at an average price of $99.33 in a transaction dated on August 1, 2016. The total value of the transaction was worth $397,320.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).